Sequoia Financial Advisors LLC Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

Sequoia Financial Advisors LLC lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 13.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 85,299 shares of the medical research company's stock after purchasing an additional 10,245 shares during the quarter. Sequoia Financial Advisors LLC's holdings in IQVIA were worth $16,762,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of IQV. Impax Asset Management Group plc raised its stake in shares of IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company's stock worth $423,885,000 after purchasing an additional 157,809 shares during the last quarter. Assetmark Inc. grew its holdings in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock worth $54,000 after acquiring an additional 196 shares during the period. Atria Investments Inc grew its holdings in IQVIA by 6.6% during the third quarter. Atria Investments Inc now owns 20,404 shares of the medical research company's stock worth $4,835,000 after acquiring an additional 1,261 shares during the period. Covestor Ltd grew its holdings in IQVIA by 34.4% during the third quarter. Covestor Ltd now owns 246 shares of the medical research company's stock worth $59,000 after acquiring an additional 63 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new position in IQVIA during the third quarter worth $57,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on IQV. BTIG Research lowered IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Truist Financial reaffirmed a "buy" rating and set a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. Stephens assumed coverage on IQVIA in a report on Friday, December 20th. They set an "overweight" rating and a $250.00 price objective on the stock. Robert W. Baird lowered their target price on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. Finally, Citigroup lowered their target price on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, IQVIA currently has an average rating of "Moderate Buy" and a consensus target price of $249.05.

IQVIA Trading Up 2.2 %

NYSE IQV traded up $3.97 during trading hours on Friday, hitting $185.40. 1,100,331 shares of the company's stock were exchanged, compared to its average volume of 1,225,762. The business's 50 day moving average is $196.63 and its 200-day moving average is $210.69. IQVIA Holdings Inc. has a 12-month low of $179.28 and a 12-month high of $256.34. The firm has a market capitalization of $32.69 billion, a P/E ratio of 24.72, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.